financetom
Business
financetom
/
Business
/
Market Chatter: Canadian Drug Maker Apotex Hires Banks to Prepare for IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Canadian Drug Maker Apotex Hires Banks to Prepare for IPO
Nov 4, 2024 11:20 AM

02:50 PM EDT, 11/01/2024 (MT Newswires) -- Canadian generic drug manufacturer Apotex Inc. is making plans for a potential initial public offering next year, according to people familiar with the matter, Bloomberg is reporting Friday.

RBC Capital Markets, Jefferies Financial Group and TD Securities are advisers for the deal, the people said, asking not to be identified discussing information that is still private. No decisions have been made yet on exact timing or size, and more banks may be added to the lineup later, they said.

Spokespeople for TD and Jefferies declined to comment. Spokespeople for RBC and Apotex didn't immediate respond to requests for comment.

Bloomberg noted that Apotex, based in Toronto, was founded in 1974 by Barry Sherman, who built it into one of the world's largest makers of generic drugs. Sherman and his wife, Honey Sherman, were found dead in their Toronto home in December 2017 in what said was a double homicide.

With a net worth of about C$3.6 billion ($2.6 billion) at the time of their deaths, they ranked as two of the wealthiest people in the world ever to be murdered, and the crime remains unsolved almost seven years later.

Apotex was sold to New York-based private equity firm SK Capital Partners in a deal that closed in 2023. The sale valued the company at between C$3 billion and C$4 billion, people with knowledge of the transaction told Bloomberg Businessweek last year.

A spokesperson for SK Capital did not reply to questions from Bloomberg News.

Earlier this year, Apotex bought Montreal-based Searchlight Pharma Inc., a specialty health-care company that focuses on selling patented medication focusing on women's health, dermatology, allergy, pain management and hospital specialty markets.

(Market Chatter news is derived from conversations with market professionals globally, and/or from other media sources. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 169.38, Change: +0.99, Percent Change: +0.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SharpLink Gaming Q3 revenue up 1,100% driven by ETH treasury strategy
SharpLink Gaming Q3 revenue up 1,100% driven by ETH treasury strategy
Nov 12, 2025
Overview * SharpLink Q3 revenue grows over 1,100% yr/yr, driven by ETH treasury strategy * Net income for Q3 rises sharply, reflecting successful ETH strategy execution * Company announces $1.5 bln stock repurchase program, indicating confidence in growth Outlook * SharpLink plans to allocate $200 mln in ETH for deployment on Consensys' Linea platform * Company focuses on long-term value...
United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing
Nov 12, 2025
04:43 PM EST, 11/12/2025 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & CEO, on November 10, 2025, sold 8,000 shares in United Therapeutics ( UTHR ) for $3,600,830. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 644,489 common shares of the company, with 130 shares held directly and 644,359 controlled indirectly. SEC...
Canadian spirits company Corby's Q1 revenue up 16% to record $75.4 mln
Canadian spirits company Corby's Q1 revenue up 16% to record $75.4 mln
Nov 12, 2025
Overview * Corby Q1 fiscal 2026 revenue grows 16% yr/yr, reaching an all-time high of C$75.4 mln * Adjusted EBITDA for Q1 reaches record C$20.3 mln, up 4% yr/yr * Adjusted net earnings for Q1 rise 8% yr/yr to C$11 mln Outlook * Company anticipates softer Q2 due to low comparative base and BCGEU strike impact * Corby expects full-year...
Fidelis Insurance Q3 premiums written rises
Fidelis Insurance Q3 premiums written rises
Nov 12, 2025
Overview * Fidelis Q3 gross premiums written grow 7.5% yr/yr * Combined ratio improves to 79.0% from 87.4% in Q3 2024 * Net income for Q3 was $130.5 mln Outlook * Fidelis targets 6-10% growth in gross premiums written for full-year 2025 * Fidelis focused on expanding underwriting partnerships amid rate pressure Result Drivers * GROSS PREMIUMS GROWTH - GPW...
Copyright 2023-2026 - www.financetom.com All Rights Reserved